Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy

被引:13
|
作者
Neubecker, Katherine [1 ]
Adams-Huet, Beverley [2 ]
Farukhi, Irfan M. [3 ]
Delapena, Rosinda C. [3 ]
Gruntmanis, Ugis [4 ,5 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Dallas Vet Affairs Med Ctr, Dept Nucl Med, Dallas, TX 75216 USA
[4] Dallas Vet Affairs Med Ctr, Dept Med, Dallas, TX 75216 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75216 USA
关键词
D O I
10.4061/2011/924595
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Decrease of bonemineral density (BMD) and fracture risk is increased in men with prostate cancer receiving androgen deprivation therapy (ADT). We looked at possible predictors of decreased BMD and increased fracture risk in men with prostate cancer; most of whom were on ADT. In a retrospective study, we analyzed serum, BMD, and clinical risk factors used in the Fracture Risk Assessment (FRAX) tool and others in 78 men with prostate cancer with reported height loss. The subjects were divided in two groups: 22 men with and 56 without vertebral fractures. 17 of the 22 men with vertebral fractures on spine X-rays did not know they had a vertebral fracture. Of those 17 men, 9 had not previously qualified for treatment based on preradiograph FRAX score calculated with BMD, and 6 based on FRAX calculated without BMD. Performing spine films increased the predictive ability of FRAX for vertebral fracture. Vertebral fracture was better predicted by FRAX for other osteoporotic fractures than FRAX for hip fractures. The inclusion of BMD in FRAX calculations did not affect the predictive ability of FRAX. The PSA level showed a positive correlation with lumbar spine BMD and accounted for about 9% of spine BMD.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy COMMENT
    Heidenreich, Axel
    Porres, Daniel
    UROLOGY, 2014, 84 (01) : 168 - 168
  • [32] Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy
    Yaturu, S
    DjeDjos, S
    Alferos, G
    Deprisco, C
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (01) : 35 - 38
  • [33] Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density.
    Alferos, MG
    Yaturu, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S243 - S243
  • [34] Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy
    Bernat, MM
    Pasini, J
    Marekovic, Z
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 589 - 591
  • [35] Bone mineral density testing after initiation of androgen deprivation therapy for prostate cancer
    Hu, Jason
    Dragomir, Alice
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 521 - 521
  • [36] Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer
    Saylor, Philip J.
    Kaufman, Donald S.
    Michaelson, M. Dror
    Lee, Richard J.
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2010, 183 (06): : 2200 - 2205
  • [37] Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Morton, Ronald A.
    Barnette, K. Gary
    Sieber, Paul R.
    Malkowicz, S. Bruce
    Rodriguez, Domingo
    Hancock, Michael L.
    Steiner, Mitchell S.
    JOURNAL OF UROLOGY, 2010, 184 (04): : 1316 - 1321
  • [38] The Prevalence Fracture Risk Factors in Men with Prostate Cancer at the Start of Androgen Deprivation Therapy
    van Oostwaard, Marsha
    van den Bergh, Joop
    de Wouw, Yes van
    Janssen-Heijnen, Maryska
    de Jong, Marc
    Weyers, Caroline
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 271 - 272
  • [39] Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Morton, Ronald A.
    Barnette, K. Gary
    Sieber, Paul R.
    Malkowicz, S. Bruce
    Rodriguez, Domingo
    Hancock, Michael L.
    Steiner, Mitchell S.
    JOURNAL OF UROLOGY, 2013, 189 (01): : S45 - S50
  • [40] The effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in men with prostate cancer: A meta-analysis
    Lau, A.
    Vinik, O.
    Alibhai, S. M. H.
    Tomlinson, G.
    Cheung, A. M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S141 - S141